There are several ICB therapies that are currently utilized in the clinic, but the most well-studied are anti-programmed cell death protein 1 (anti-PD-1), which is predominantly found on T cells, and anti-programmed cell death ligand 1 (anti-PD-L1), which is expressed on tumor and myeloid cells[3]. This evidence concerns the gene PDCD1 and neoplasm.